

RESPONSE TO RESTRICTION REQUIREMENT  
U.S. Appln. No. 09/786,319

IN THE CLAIMS:

Please amend the claims as follows:

Claim 1. (Amended) A method of suppressing antigen presenting cell-mediated lymphocyte proliferation in a mammalian host pre-exposed to a particular antigen comprising the step of administering to said host an effective amount of Zot, said amount effective to down-regulate the activity of said antigen presenting cell.

Claim 2. (Amended) A method of suppressing antigen presenting cell-mediated lymphocyte proliferation to a particular antigen in a mammalian host comprising the step of administering to said host an effective amount of Zot in combination with said particular antigen, said amount effective to down-regulate the activity of said antigen presenting cell.

Claim 3. (Amended) A method of treating a mammalian host afflicted with an auto-immune or immune-related disorder or disease comprising the step of administering to said host an effective amount of Zot, said amount effective to down-regulate antigen presenting cell-mediated lymphocyte proliferation.

Claim 4. (Amended) A method of treating a mammalian host afflicted with an auto-immune or immune-related disorder or disease comprising the step of administering to said host an effective amount of Zot in combination with an antigen specific to said disease or disorder, said amount effective to down-regulate antigen presenting cell-mediated lymphocyte proliferation.

Claim 5. (Amended) A method of treating of a mammalian host suffering from immune rejection subsequent to tissue or

RESPONSE TO RESTRICTION REQUIREMENT

U.S. Appln. No. 09/786,319

organ transplantation comprising the step of administering to said host an effective amount of Zot, said amount effective to down-regulate antigen presenting cell-mediated lymphocyte proliferation.

Claim 6. (Amended) A method of treating a mammalian host suffering from immune rejection subsequent to tissue or organ transplantation comprising the step of administering to said host an effective amount of Zot in combination with a specific transplantation antigen, said amount effective to down-regulate antigen presenting cell-mediated lymphocyte proliferation.

*B1*  
Claim 7. (Amended) A method of treating a mammalian host afflicted with an inflammatory or allergic diseases or disorders comprising the step of administering an effective of Zot, said amount effective to down-regulate antigen presenting cell-mediated lymphocyte proliferation.

Claim 8. (Amended) A method for the treatment of a mammalian host afflicted with an inflammatory or allergic diseases or disorders comprising the step of administering an effective of Zot in combination with a specific inflammatory related antigen or allergen, said amount effective to down-regulate antigen presenting cell-mediated lymphocyte proliferation.

---

*B2*  
Claim 13. (Amended) The method of Claims 1 to 8, wherein said Zot is administered in admixture with at least one of the group consisting of a pharmaceutically acceptable carrier, adjuvant and delivery vehicle.

RESPONSE TO RESTRICTION REQUIREMENT  
U.S. Appln. No. 09/786,319

---

Claim 15. (Amended) The method of Claim 2, 4, 6 or 8, wherein said antigen and said Zot are concomitantly or sequentially administered.

*B3*  
Claim 16. (Amended) The method of Claims 1 to 8, wherein said Zot is administered to a mucosal surface.

Claim 17. (Amended) The method of Claim 2, 4, 6 or 8, wherein said antigen and said Zot are administered to a mucosal surface.

---

Claim 20. (Amended) The method of Claims 1 to 8, wherein said Zot is administered parenterally.

Claim 21. (Amended) The method of Claim 2, 4, 6 or 8, wherein said antigen and said Zot are administered parenterally.

Claim 22. (Amended) The method of Claims 1 to 8, wherein the mode of administering said Zot is selected from the group consisting of intravenous, intradermal, intramuscular, and subcutaneous.

*B4*  
Claim 23. (Amended) The method of Claim 2, 4, 6 or 8, wherein the mode of administering said antigen and said Zot is selected from the group consisting of intravenous, intradermal, intramuscular, and subcutaneous.

Claim 24. (Amended) A method of suppressing antigen presenting cell-mediated lymphocyte proliferation in a culture of cells pre-exposed to a particular antigen comprising the step of contacting the culture with an amount of Zot, said amount effective to down regulate the activity of said antigen presenting cell.

Claim 25. (Amended) A method of suppressing antigen presenting cell-mediated lymphocyte proliferation in a culture